Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

NCT01078636
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
Conditions
Brain Imaging, Mild Cognitive Impairment, Alzheimer Disease, Deep Brain Stimulation
Interventions
Excitation, Inhibition
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Alzheimer Disease
Interventions
Low Dose Benfotiamine, High Dose Benfotiamine, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years to 89 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Rapamycin, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
55 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Mild Cognitive Impairment
Interventions
NewGam 10% IVIG, Placebo
Drug · Other
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Sacramento, California
Conditions
Alzheimer Disease
Interventions
PQ912, Placebo
Drug · Other
Lead sponsor
Vivoryon Therapeutics N.V.
Industry
Eligibility
50 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
Not listed Not applicable Interventional Accepts healthy volunteers

Juice Plus Supplement Clinical Trial

NCT04656860
Conditions
Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Juice Plus+
Dietary Supplement
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama
Recruiting No phase listed Observational Accepts healthy volunteers

Predicting Pre-dementia

NCT07516119
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
Interventions
Not listed
Lead sponsor
Prevention Research Consortium Corp.
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Not listed No phase listed Observational Accepts healthy volunteers

Predictors of Cognitive Decline in Normal Aging

NCT00094939
Conditions
Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
North Coast Medical Activadose II
Device
Lead sponsor
The Mind Research Network
Other
Eligibility
50 Years to 90 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Ana, California
Conditions
Alzheimer's Disease (Incl Subtypes), Dementia, Mild Cognitive Impairment
Interventions
Dance Group, Non-Group Dance, Social Group, No Contact
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 85 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Alzheimer's Disease
Interventions
Placebo, Bepranemab
Other · Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
50 Years to 80 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Fresno, California • Fullerton, California • Irvine, California + 34 more
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cognitive Dysfunction
Interventions
adMSC
Biological
Lead sponsor
Paul E Schulz
Other
Eligibility
60 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Florbetapir F 18 PET Scan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
77
States / cities
Anaheim, California • Imperial, California • Irvine, California + 59 more
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Dementia, Cognitive Decline
Interventions
Acceptability and Feasibility of Twistle messaging for PDM+ patients
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
3,454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Withdrawn No phase listed Observational Accepts healthy volunteers

A Composite MR Neuroimaging Marker for Alzheimer's Disease

NCT01615666
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Dementia (AD), Subjective Cognitive Decline (SCD), Cognitive Aging
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed No phase listed Observational Accepts healthy volunteers

Brain Health & the Microbiome

NCT06039267
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer Disease 1
Interventions
Gut Microbiome Testing
Other
Lead sponsor
George Washington University
Other
Eligibility
50 Years to 90 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Recruiting No phase listed Observational Accepts healthy volunteers

Wake Forest Alzheimer's Disease Clinical Core

NCT03140865
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Winston-Salem, North Carolina